Data as of .
BIOY vs TDVI: which paid, and which earned it?
BIOY and TDVI both write options for income.
What they hold in common
By the books each fund has filed, BIOY and TDVI hold 0% of their money in the same securities at the same weight.
| Only in BIOY | Only in TDVI |
|---|---|
| Treasury Bill 100.00% | Texas Instruments Incorporated 8.22% |
| Oracle Corporation 7.97% | |
| International Business Machines Corporat 7.90% | |
| Microsoft Corporation 7.83% | |
| Broadcom Inc. 7.77% | |
| Taiwan Semiconductor Manufacturing Compa 4.21% | |
| QUALCOMM Incorporated 4.19% | |
| Analog Devices, Inc. 3.19% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and Sep 18, 2026.
Performance, window by window
| Window | Total return | Cash paid | Against the benchmark | |||
|---|---|---|---|---|---|---|
| BIOY | TDVI | BIOY | TDVI | BIOY | TDVI | |
| 3 months | +2.5% | −2.9% | 14.1% | 1.9% | −9.0 pts | −2.1 pts |
| 6 months | not published | +21.2% | not published | 4.5% | not published | −19.2 pts |
| 1 year | not published | +17.1% | not published | 8.1% | not published | −20.9 pts |
| 3 years | not published | +101.3% | not published | 31.3% | not published | −26.7 pts |
| Since launch | +2.0% | +101.0% | 20.6% | 31.3% | −15.3 pts | −29.0 pts |
| BIOY GraniteShares YieldBOOST Biotech ETF Synthetic covered call on XBI, paying weekly | TDVI FT Vest Technology Dividend Target Income ETF Dividend stocks with call overlay on XLK, paying monthly | |
|---|---|---|
| Issuer | GraniteShares | First Trust |
| Strategy | synthetic covered call | dividend stocks with call overlay |
| Benchmark | Biotech (XBI), used as the proxy | Technology sector (XLK) |
| Pays | weekly | monthly |
| Payout rate, annualized | 60.0% | 7.9% |
| Expense ratio | 1.07% | 0.75% |
| Cash paid, 1 year | 20.6% (since launch on May 5, 2026) | 8.1% |
| Price change, 1 year | −19.0% | +8.2% |
| Total return, 1 year | +2.0% (since launch on May 5, 2026) | +17.1% |
| Benchmark return, 1 year | +17.3% | +38.0% |
| Ahead or behind | −15.3 pts | −20.9 pts |
| Return of capital, latest estimate | 96% | not published |
| Age | 136 days | 1135 days |
| Net assets | $1m | $631m |
BIOY in plain words
Over the period since launch on May 5, 2026 to Sep 18, 2026, BIOY paid 20.6% of its starting value in cash distributions while its price fell 19.0%. With every distribution reinvested, the fund returned +2.0%. Biotech (XBI), used as the proxy returned +17.3% over the same days, so a holder was behind by 15.3 pts. At its price on Sep 18, 2026 the latest distribution annualizes to 60.0%, paid weekly. GraniteShares estimates that 96% of the distribution paid Aug 25, 2026 was a return of capital (19a-1 notice, estimated, a tax characterization rather than a measure of erosion).
TDVI in plain words
Over the year to Sep 18, 2026, TDVI paid 8.1% of its starting value in cash distributions while its price rose 8.2%. With every distribution reinvested, the fund returned +17.1%. Technology sector (XLK) returned +38.0% over the same days, so a holder was behind by 20.9 pts. At its price on Sep 18, 2026 the latest distribution annualizes to 7.9%, paid monthly.
Questions people ask
- Which is cheaper, BIOY or TDVI?
- BIOY charges 1.07% a year and TDVI charges 0.75%, so TDVI is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, BIOY against TDVI, data as of Sep 18, 2026. https://etfiq.com/compare/income/bioy-vs-tdvi Free to use with attribution; the underlying files are at Open data.